BiomX (NYSEAMERICAN:PHGE) Price Target Raised to $21.00 at HC Wainwright

BiomX (NYSEAMERICAN:PHGE) had its target price lifted by HC Wainwright from $2.00 to $21.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

BiomX Stock Down 2.3 %

NYSEAMERICAN:PHGE opened at $0.56 on Tuesday. BiomX has a fifty-two week low of $0.48 and a fifty-two week high of $4.99. The firm has a market cap of $10.10 million, a PE ratio of -0.17 and a beta of 1.27.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).